EA201690686A1 - Способ профилактики или лечения системной красной волчанки и/или волчаночного нефрита - Google Patents
Способ профилактики или лечения системной красной волчанки и/или волчаночного нефритаInfo
- Publication number
- EA201690686A1 EA201690686A1 EA201690686A EA201690686A EA201690686A1 EA 201690686 A1 EA201690686 A1 EA 201690686A1 EA 201690686 A EA201690686 A EA 201690686A EA 201690686 A EA201690686 A EA 201690686A EA 201690686 A1 EA201690686 A1 EA 201690686A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- lupine
- jade
- prevention
- treatment
- systemic red
- Prior art date
Links
- 241000219745 Lupinus Species 0.000 title 1
- 239000010977 jade Substances 0.000 title 1
- 206010025135 lupus erythematosus Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 230000009885 systemic effect Effects 0.000 title 1
- -1 {[(2,5-dichlorobenzoyl) amino] acetyl} amino Chemical group 0.000 abstract 2
- 208000005777 Lupus Nephritis Diseases 0.000 abstract 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361886403P | 2013-10-03 | 2013-10-03 | |
| PCT/US2014/058738 WO2015051067A1 (en) | 2013-10-03 | 2014-10-02 | Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201690686A1 true EA201690686A1 (ru) | 2016-08-31 |
Family
ID=51842818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201690686A EA201690686A1 (ru) | 2013-10-03 | 2014-10-02 | Способ профилактики или лечения системной красной волчанки и/или волчаночного нефрита |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20160250238A1 (https=) |
| EP (1) | EP3052105A1 (https=) |
| JP (1) | JP2016531886A (https=) |
| KR (1) | KR20160058886A (https=) |
| CN (1) | CN105705149A (https=) |
| BR (1) | BR112016007237A2 (https=) |
| CA (1) | CA2925935A1 (https=) |
| EA (1) | EA201690686A1 (https=) |
| MX (1) | MX2016003979A (https=) |
| WO (1) | WO2015051067A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020000092A1 (en) * | 2018-06-27 | 2020-01-02 | Algernon Pharmaceuticals Inc. | The use of actarit in the prophylaxis or treatment of renal fibrosis or kidney disease |
| JP2023525259A (ja) * | 2020-05-07 | 2023-06-15 | 諾羅瑞韋株式会社 | うつ病治療のためのシクロセリンおよびペントキシフィリンの併用療法｛Ｃｙｃｌｏｓｅｒｉｎｅ ａｎｄ Ｐｅｎｔｏｘｉｆｙｌｌｉｎｅ Ｃｏｍｂｉｎａｔｉｏｎ Ｔｈｅｒａｐｙ ｆｏｒ Ｔｒｅａｔｍｅｎｔ ｏｆ Ｄｅｐｒｅｓｓｉｏｎ｝ |
| CN121041156A (zh) * | 2025-08-27 | 2025-12-02 | 复皙药业(上海)有限公司 | 含有替普瑞酮的具有祛红功效的膏霜及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| JP4162491B2 (ja) | 2001-01-25 | 2008-10-08 | アメリカ合衆国 | ボロン酸化合物製剤 |
| AU2007357338B2 (en) * | 2007-08-06 | 2014-03-20 | Takeda Pharmaceutical Company Limited | Proteasome inhibitors |
| US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
| CA2727862C (en) * | 2008-06-17 | 2016-04-19 | Millennium Pharmaceuticals, Inc. | Boronate ester compounds and pharmaceutical compositions thereof |
| AR075090A1 (es) | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
| AR077033A1 (es) | 2009-06-11 | 2011-07-27 | Hoffmann La Roche | Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas |
| US8513218B2 (en) | 2010-03-31 | 2013-08-20 | Millennium Pharmaceuticals, Inc. | Derivatives of 1-amino-2-cyclopropylethylboronic acid |
| TW201309303A (zh) | 2011-03-03 | 2013-03-01 | Cephalon Inc | 用於治療狼瘡的蛋白酶體抑制劑 |
| US20140121182A1 (en) * | 2011-06-22 | 2014-05-01 | Cephalon, Inc. | Proteasome inhibitors and processes for their preparation, purification and use |
-
2014
- 2014-10-02 MX MX2016003979A patent/MX2016003979A/es unknown
- 2014-10-02 US US15/026,417 patent/US20160250238A1/en not_active Abandoned
- 2014-10-02 JP JP2016519782A patent/JP2016531886A/ja active Pending
- 2014-10-02 BR BR112016007237A patent/BR112016007237A2/pt not_active IP Right Cessation
- 2014-10-02 CA CA2925935A patent/CA2925935A1/en not_active Abandoned
- 2014-10-02 WO PCT/US2014/058738 patent/WO2015051067A1/en not_active Ceased
- 2014-10-02 CN CN201480060987.4A patent/CN105705149A/zh active Pending
- 2014-10-02 EP EP14790872.7A patent/EP3052105A1/en not_active Withdrawn
- 2014-10-02 EA EA201690686A patent/EA201690686A1/ru unknown
- 2014-10-02 KR KR1020167010114A patent/KR20160058886A/ko not_active Withdrawn
-
2017
- 2017-12-12 US US15/838,595 patent/US20180099000A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20160250238A1 (en) | 2016-09-01 |
| CN105705149A (zh) | 2016-06-22 |
| WO2015051067A1 (en) | 2015-04-09 |
| KR20160058886A (ko) | 2016-05-25 |
| CA2925935A1 (en) | 2015-04-09 |
| MX2016003979A (es) | 2016-06-15 |
| EP3052105A1 (en) | 2016-08-10 |
| BR112016007237A2 (pt) | 2017-09-12 |
| US20180099000A1 (en) | 2018-04-12 |
| JP2016531886A (ja) | 2016-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501414A1 (en) | Amino acid compositions and methods for the treatment of liver diseases | |
| PH12019501339A1 (en) | Amino acid compositions and methods for the treatment of muscle diseases and disorders | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| UA117451C2 (uk) | Терапевтично активні сполуки і способи їх застосування | |
| EA201691155A1 (ru) | Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств | |
| MX377629B (es) | Composiciones farmacéuticas tópicas. | |
| IN2015DN00376A (https=) | ||
| PH12016502355B1 (en) | Pharmaceutical composition | |
| IN2015DN00450A (https=) | ||
| MX2021013880A (es) | Polimeros enlazados al proton para administracion oral. | |
| EA201690513A1 (ru) | Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний | |
| MX2016002580A (es) | Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas. | |
| EA201500851A1 (ru) | ЭСТРА-1,3,5(10),16-ТЕТРАЕН-3-КАРБОКСАМИДЫ ДЛЯ ИНГИБИРОВАНИЯ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ (AKR1C3) | |
| EA201591378A1 (ru) | Композиции неорганических наночастиц в комбинации с ионизирующим излучением для лечения рака | |
| EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
| EA201491500A1 (ru) | Способы лечения фиброза | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| TW201613578A (en) | Pharmaceutical combinations | |
| MX382776B (es) | Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica. | |
| EA201690686A1 (ru) | Способ профилактики или лечения системной красной волчанки и/или волчаночного нефрита | |
| WO2014152437A3 (en) | Methods of use for an antimicrobial peptide | |
| EP4219534A3 (en) | Methods for treatment of and prophylaxis against inflammatory disorders | |
| CN106456621A8 (zh) | 用于治疗hcv的方法 | |
| MY184269A (en) | Broad-spectrum anti-influenza virus therapeutic peptides | |
| EA201690070A1 (ru) | Применение аргинина и/или цитруллина для лечения и/или профилактики остеоартроза |